Risk factors for pleural effusion recurrence in patients with malignancy.


Journal

Respirology (Carlton, Vic.)
ISSN: 1440-1843
Titre abrégé: Respirology
Pays: Australia
ID NLM: 9616368

Informations de publication

Date de publication:
01 2019
Historique:
received: 20 01 2018
revised: 09 04 2018
accepted: 07 06 2018
pubmed: 3 7 2018
medline: 25 1 2020
entrez: 3 7 2018
Statut: ppublish

Résumé

The main purpose of treatment in patients with malignant pleural effusion (MPE) is symptom palliation. Currently, patients undergo repeat thoracenteses prior to receiving a definitive procedure as clinicians are not aware of the risk factors associated with fluid recurrence. The primary objective of this study was to identify risk factors associated with recurrent symptomatic MPE. Retrospective multicentre cohort study of patients who underwent first thoracentesis was performed. The primary outcome was time to fluid recurrence requiring intervention in patients with evidence of metastatic disease. We used a cause-specific hazard model to identify risk factors associated with fluid recurrence. We also developed a predictive model, utilizing Fine-Gray subdistribution hazard model, and externally validated the model. A total of 988 patients with diagnosed metastatic disease were included. Cumulative incidence of recurrence was high with 30% of patients recurring by day 15. On multivariate analysis, size of the effusion on chest X-ray (up to the top of the cardiac silhouette (hazard ratio (HR): 1.84, 95% CI: 1.21-2.80, P = 0.004) and above the cardiac silhouette (HR: 2.22, 95% CI: 1.43-3.46, P = 0.0004)), larger amount of pleural fluid drained (HR: 1.06, 95% CI: 1.04-1.07, P < 0.0001) and higher pleural fluid LDH (HR: 1.008, 95% CI: 1.004-1.011, P < 0.0001) were associated with increased hazard of recurrence. Negative cytology (HR: 0.52, 95% CI: 0.43-0.64, P < 0.0001) was associated with decreased hazard of recurrence. The model had low prediction accuracy. Pleural effusion size, amount of pleural fluid drained, LDH and pleural fluid cytology were found to be risk factors for recurrence.

Sections du résumé

BACKGROUND AND OBJECTIVE
The main purpose of treatment in patients with malignant pleural effusion (MPE) is symptom palliation. Currently, patients undergo repeat thoracenteses prior to receiving a definitive procedure as clinicians are not aware of the risk factors associated with fluid recurrence. The primary objective of this study was to identify risk factors associated with recurrent symptomatic MPE.
METHODS
Retrospective multicentre cohort study of patients who underwent first thoracentesis was performed. The primary outcome was time to fluid recurrence requiring intervention in patients with evidence of metastatic disease. We used a cause-specific hazard model to identify risk factors associated with fluid recurrence. We also developed a predictive model, utilizing Fine-Gray subdistribution hazard model, and externally validated the model.
RESULTS
A total of 988 patients with diagnosed metastatic disease were included. Cumulative incidence of recurrence was high with 30% of patients recurring by day 15. On multivariate analysis, size of the effusion on chest X-ray (up to the top of the cardiac silhouette (hazard ratio (HR): 1.84, 95% CI: 1.21-2.80, P = 0.004) and above the cardiac silhouette (HR: 2.22, 95% CI: 1.43-3.46, P = 0.0004)), larger amount of pleural fluid drained (HR: 1.06, 95% CI: 1.04-1.07, P < 0.0001) and higher pleural fluid LDH (HR: 1.008, 95% CI: 1.004-1.011, P < 0.0001) were associated with increased hazard of recurrence. Negative cytology (HR: 0.52, 95% CI: 0.43-0.64, P < 0.0001) was associated with decreased hazard of recurrence. The model had low prediction accuracy.
CONCLUSION
Pleural effusion size, amount of pleural fluid drained, LDH and pleural fluid cytology were found to be risk factors for recurrence.

Identifiants

pubmed: 29966171
doi: 10.1111/resp.13362
pmc: PMC7315912
mid: NIHMS1596420
doi:

Substances chimiques

L-Lactate Dehydrogenase EC 1.1.1.27

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

76-82

Subventions

Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL007534
Pays : United States
Organisme : NCI NIH HHS
ID : P30CA016672
Pays : United States

Informations de copyright

© 2018 Asian Pacific Society of Respirology.

Références

J Bronchology Interv Pulmonol. 2015 Jul;22(3):215-25
pubmed: 26165892
Respiration. 2004 Nov-Dec;71(6):559-66
pubmed: 15627865
Am J Epidemiol. 2009 Jul 15;170(2):244-56
pubmed: 19494242
Support Care Cancer. 2013 Nov;21(11):3109-16
pubmed: 23842597
Cancer. 1999 Nov 15;86(10):1992-9
pubmed: 10570423
Circulation. 2016 Feb 9;133(6):601-9
pubmed: 26858290
Am J Respir Crit Care Med. 2000 Nov;162(5):1987-2001
pubmed: 11069845

Auteurs

Horiana B Grosu (HB)

Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Sofia Molina (S)

Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
School of Medicine and Health Sciences TecSalud, Monterrey, Mexico.

Roberto Casal (R)

Pulmonary Department, Michael DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX, USA.

Juhee Song (J)

Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Liang Li (L)

Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Javier Diaz-Mendoza (J)

Pulmonary Department, Henry Ford Hospital, Detroit, MI, USA.

Chakravarthy Reddy (C)

Pulmonary Department, University of Utah Health Care, Salt Lake City, UT, USA.

Lonny Yarmus (L)

Pulmonary Department, Johns Hopkins University, Baltimore, MD, USA.

Dante Schiavo (D)

Pulmonary Department, Mayo Clinic, Rochester, MN, USA.

Michael Simoff (M)

Pulmonary Department, Henry Ford Hospital, Detroit, MI, USA.

Jared Johnstun (J)

Pulmonary Department, University of Utah Health Care, Salt Lake City, UT, USA.

Abu-Awwad Raid (AA)

Pulmonary Department, Michael DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX, USA.

David Feller-Kopman (D)

Pulmonary Department, Johns Hopkins University, Baltimore, MD, USA.

Hans Lee (H)

Pulmonary Department, Johns Hopkins University, Baltimore, MD, USA.

Sarina Sahetya (S)

Pulmonary Department, Johns Hopkins University, Baltimore, MD, USA.

Finbar Foley (F)

Pulmonary Department, Mayo Clinic, Rochester, MN, USA.

Fabien Maldonado (F)

Pulmonary Department, Vanderbilt University, Nashville, TN, USA.

Xin Tian (X)

Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Laila Noor (L)

Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Russell Miller (R)

Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Lakshmi Mudambi (L)

Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Timothy Saettele (T)

Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Macarena Vial-Rodriguez (M)

Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Gerogie A Eapen (GA)

Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

David E Ost (DE)

Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH